IL322112A - שיטות לטיפול בגליובלסטומה - Google Patents

שיטות לטיפול בגליובלסטומה

Info

Publication number
IL322112A
IL322112A IL322112A IL32211225A IL322112A IL 322112 A IL322112 A IL 322112A IL 322112 A IL322112 A IL 322112A IL 32211225 A IL32211225 A IL 32211225A IL 322112 A IL322112 A IL 322112A
Authority
IL
Israel
Prior art keywords
weeks
radiotherapy
dose
radiopharmaceutical compound
subject
Prior art date
Application number
IL322112A
Other languages
English (en)
Inventor
Stephen Moran
Paola Daniela Aimone
Original Assignee
Novartis Ag
Stephen Moran
Paola Daniela Aimone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Stephen Moran, Paola Daniela Aimone filed Critical Novartis Ag
Publication of IL322112A publication Critical patent/IL322112A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL322112A 2023-02-08 2024-02-06 שיטות לטיפול בגליובלסטומה IL322112A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363483784P 2023-02-08 2023-02-08
PCT/IB2024/051083 WO2024165990A1 (en) 2023-02-08 2024-02-06 Methods for treating glioblastoma

Publications (1)

Publication Number Publication Date
IL322112A true IL322112A (he) 2025-09-01

Family

ID=89897182

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322112A IL322112A (he) 2023-02-08 2024-02-06 שיטות לטיפול בגליובלסטומה

Country Status (9)

Country Link
EP (1) EP4661919A1 (he)
JP (1) JP2026505341A (he)
KR (1) KR20250140611A (he)
CN (1) CN120641139A (he)
AU (1) AU2024217776A1 (he)
IL (1) IL322112A (he)
MX (1) MX2025009185A (he)
TW (1) TW202432192A (he)
WO (1) WO2024165990A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025126151A1 (en) * 2023-12-15 2025-06-19 Novartis Ag Methods for treating breast cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728088A (zh) 2019-09-16 2022-07-08 诺华股份有限公司 稳定的浓缩的放射性药物组合物
TWI878344B (zh) 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識ｇｒｐｒアンタゴニスト
WO2021171261A1 (en) 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor

Also Published As

Publication number Publication date
MX2025009185A (es) 2025-09-02
WO2024165990A1 (en) 2024-08-15
EP4661919A1 (en) 2025-12-17
JP2026505341A (ja) 2026-02-13
AU2024217776A1 (en) 2025-07-17
TW202432192A (zh) 2024-08-16
CN120641139A (zh) 2025-09-12
KR20250140611A (ko) 2025-09-25

Similar Documents

Publication Publication Date Title
US10646599B2 (en) Method for upregulating antigen expression
HK1256497A1 (en) Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
JP2024541595A (ja) 放射線医薬的治療方法及び使用
Zhu et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
IL322112A (he) שיטות לטיפול בגליובלסטומה
JP2024544874A (ja) 肺がん治療のための組み合わせ療法
IL322257A (he) שיטות לטיפול בסרטן השד
IL303930A (he) אנטגוניסט רדיואקטיבי לאלפא v בטא 3 ו\או אלפא v בטא 4 אינטגרינים ושימוש שלהם בתור חומר תראגוניסטי
WO2025126151A1 (en) Methods for treating breast cancer
CA3234495A1 (en) Combination therapy of radionuclide complex
Wenker et al. CAIX-targeted α therapy directed against hypoxic tumor cells in combination with immune checkpoint inhibitors in a syngeneic mouse tumor model
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법
WO2026039638A1 (en) Tshr-targeted radiopharmaceuticals for diagnosis and therapy of thyroid cancer
Castro European Association of Nuclear Medicine 28th Annual Congress. Hamburg, Germany-October 10-14, 2015
Mishra et al. GALLIUM-68-LABELED PEPTIDE PET QUANTIFIES TUMOR EXPOSURE OF PD-L1
HK1217438B (en) Combination therapy comprising rituximab and the radiolabeled hh1 monoclonal antibody